Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy

• Status: Completed
• Trial end date: 2019-12-10
• Target enrollment: 0
• Participant gender: Female

Summary

the study aim to protect patients received anthracyclines containing chemotherapy from cardiotoxcity induced by anthracyclines derivatives. by using L-carnitine and Silymarin for protection the heart from anthracyclines toxicities, and in addition its a comparitive study between L-carnitine and Silymarin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Horus University
• Treatments: Silymarin

Criteria

Inclusion Criteria:

• cancer patients receiving anthracycline chemotherapy in their protocol alone (without any cardioprotective agent),

• aged 20-60 and

• female patients were included.

Exclusion Criteria:

• patients with a history of heart failure, arrhythmia, history of cardiac catheterizations or, history of angina, uncontrolled hypertension and uncontrolled diabetes,

• patients with impaired liver function tests,

• previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens,

• previous history of chest wall irradiation.

• Brain metastasis,

• pregnant patients and

• patients who refused informed consent,